索拉非尼治疗转移性肾细胞癌中原发灶病理特征的预后价值。
Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.
作者信息
Gu Weijie, Wang Beihe, Gan Hualei, Zhu Yao, Wang Hongkai, Shi Guohai, Zhou Liangpin, Zhang Hailiang, Ye Dingwei
机构信息
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
出版信息
Future Oncol. 2016 Aug;12(15):1783-93. doi: 10.2217/fon-2016-0030. Epub 2016 May 13.
AIM
This study aimed to investigate whether the pathological features of primary lesions show additional prognostic value in patients with metastatic renal cell carcinoma who are treated with sorafenib.
PATIENTS & METHODS: A consecutive cohort of 284 patients was included from Fudan University Shanghai Cancer Center between 2007 and 2013. The association between survival and pathological features of primary tumors was assessed using the Cox proportional hazards model. The incremental value of prognostication was evaluated.
RESULTS
We found that the pathological features of primary lesions provided added prognostic value over the Memorial Sloan-Kettering Cancer Center model in patients with metastatic renal cell carcinoma who were treated with sorafenib.
CONCLUSION
Addition of a pathological score in the clinical setting could better identify patients at risk of poor survival.
目的
本研究旨在探讨在接受索拉非尼治疗的转移性肾细胞癌患者中，原发灶的病理特征是否具有额外的预后价值。
患者与方法
纳入2007年至2013年间来自复旦大学附属上海肿瘤医院的284例连续队列患者。使用Cox比例风险模型评估生存与原发肿瘤病理特征之间的关联。评估预后的增量价值。
结果
我们发现，在接受索拉非尼治疗的转移性肾细胞癌患者中，原发灶的病理特征比纪念斯隆凯特琳癌症中心模型具有更高的预后价值。
结论
在临床环境中增加病理评分可以更好地识别生存不良风险患者。
Zotero 插件